Streetbeat News

Revenues

BABA

JD

Alibaba Group Holding Limited (NYSE:BABA) has launched a live commerce company under Taobao Live to diversify its host base and combat competition from other online retailers. This initiative aims to nurture a robust live commerce ecosystem by offering new hosts comprehensive services, including business connections and financial management, with support such as guaranteed income during a six-month development period. The strategy is part of Alibaba's broader effort to revitalize its live commerce offering and maintain its competitive edge, amidst challenges from platforms like Douyin and legal troubles. Alibaba's international e-commerce business unit reported a 44% revenue increase to $4 billion in the December quarter.

Portfolio Pulse from Anusuya Lahiri

February 21, 2024 | 1:40 pm

COYA

Coya Therapeutics is expanding its COYA 302 product into Alzheimer's Disease, leveraging its proprietary low-dose interleukin-2 formulation and CTLA4-Ig combination. This expansion follows partnerships and planned IND filings for ALS, FTD, and PD, with a double-blind trial for LD IL-2 in AD ongoing. The company highlights its 'Pipeline in a Product' approach, aiming to address neurodegenerative diseases' complex immune pathways. With a two-year cash runway and anticipated milestones in 2024, Coya aims to deliver therapies for neurodegenerative diseases affecting millions in the U.S.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:32 pm

MRVI

TriLink BioTechnologies, a subsidiary of Maravai LifeSciences (NASDAQ:MRVI), has secured patents in China and Canada for its CleanCap® Capping Technology, crucial for mRNA-based therapeutics and vaccines production. These patents add to the global IP portfolio, with CleanCap® already patented in major markets including the US and EU. The technology enhances mRNA production efficiency and has been used in COVID-19 vaccines. TriLink's CleanCap® M6 analog, launched last May, promises to further reduce manufacturing times and costs while increasing protein expression and mRNA yields.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:14 pm

MTEK

Maris-Tech Ltd. has received a repeat order worth around $600,000 from a defense industry company, with an option to increase the order to approximately $730,000. This indicates a continuing relationship and trust between Maris-Tech and its client in the defense sector, potentially signaling strong performance and reliability of Maris-Tech's products and services.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:11 pm

CHPT

ChargePoint Holdings (NYSE:CHPT) has been evaluated by 7 analysts over the last three months, showing a mix of bullish and indifferent sentiments. The average 12-month price target is now $2.77, significantly lower than the previous $6.58. The company's financial performance indicates challenges in revenue growth, net margin, ROE, ROA, and debt management, despite its leading position in the EV charging infrastructure market.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 1:00 pm

BCYC

Bicycle Therapeutics (NASDAQ:BCYC) received mixed analyst ratings with a shift towards bullish sentiment in the last quarter. The average 12-month price target is now $43.25, down from $49.00, indicating a 11.73% decrease. The company's financial performance shows strong revenue growth and net margin, but lags in ROA and has a prudent debt management strategy. Its main focus is on developing a novel class of medicines for oncology indications.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 1:00 pm

ENVB

Enveric Biosciences announced that its novel compounds, protected under its intellectual property portfolio, offer potential licensing opportunities and non-dilutive revenue streams. This development could enhance the company's financial stability and growth prospects without diluting existing shareholders' equity.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:00 pm

PHIN

PHINIA forecasts FY24 sales to be between $3.42B-$3.57B with adjusted sales in the range of $3.40B-$3.55B. The company also anticipates generating $160M-$200M in adjusted free cash flow.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:59 pm

ALIT

Alight has provided its financial projections for FY24, expecting revenue to be in the range of $3.55B-$3.61B, which is below the market estimate of $3.71B. However, its projected adjusted EPS of $0.72-$0.77 is around the market estimate of $0.73.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:48 pm

KHC

Kraft Heinz reiterates its 2024 financial outlook, expecting organic net sales growth of 0%-2%, adjusted operating income growth of 2%-4%, and adjusted EPS of $3.01-$3.07, aligning with a $3.03 estimate. The company anticipates positive price contributions and volume increases in the second half, with a modest expansion in adjusted gross profit margin. Challenges include a potential $45 million impact from foreign currency and debt refinancing.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:41 pm